1. Eli Lilly's 'Deal Man' Jake van Naarden in Hyperdrive as Merck's $7B Terns Buy Sparks Debate
Eli Lilly's chief dealmaker, Jake van Naarden, is operating at an intense pace, signaling a potential surge in strategic activity that could reshape the biopharma landscape. His relentless schedule is a key indicator of the competitive pressure and capital deployment underway at one of the industry's most influential p...